Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China

References

• International Diabetes Federation. About diabetes: types of diabetes. Brussels, Belgium. http://www.idf.org/about-diabetes. Accessed March 10, 2014.
   Google Scholar
• Chinese Diabetes Society. Chinese guideline for Type 2 diabetes prevention (2013). Chinese J Diabetes 2014;22:2-42
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium. 2014. http://www.idf.org/diabetesatlas/update-2014. Accessed 16 April 2015
   Google Scholar
• Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and women in China. New Engl J Med 2010;362:1090-101
   PubMed Web of Science ®Google Scholar
• Dong Y, Gao W, Nan H, et al. Prevalence of Type 2 diabetes in urban and rural Chinese populations in Qingdao, China. Diabet Med 2005;22:1427-33
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang LM, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-58
   PubMed Web of Science ®Google Scholar
• Tang L, Chen XB, Chen HY, et al. Economic burden of Type 2 Diabetes mellitus and its complications in Urban China. Chinese Health Econ 2003;22:21-3
   Google Scholar
• Wang W, McGreevey WP, Fu C, et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care 2009;15:593-601
   PubMed Web of Science ®Google Scholar
• Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil H, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Ji L, Lu J, Weng J, et al. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J Diabetes 2015;7:166-73
   PubMedGoogle Scholar
• Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-84
   PubMed Web of Science ®Google Scholar
• Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 2003;25:799-816
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
   PubMed Web of Science ®Google Scholar
• Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 Diabetes. JAMA 2010;303:1410-18
   PubMed Web of Science ®Google Scholar
• Peters AL. Patient and treatment perspectives: revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Clev Clin J Med 2009;76(5 Suppl):S20-S27
   PubMedGoogle Scholar
• Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-66
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
   PubMed Web of Science ®Google Scholar
• Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9
   PubMed Web of Science ®Google Scholar
• Alvarez GF, Tofe PS, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(1 Suppl):25-32
   PubMedGoogle Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med 2009;121:94-107
   PubMed Web of Science ®Google Scholar
• Bodegard J, Sundstrom J, Svennblad B, et al. Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients. Diabetes Metab 2013;39:306-13
   PubMed Web of Science ®Google Scholar
• Bolin K, Gip C, Mork AC, et al. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005–a register-based approach. Diabet Med 2009;26:928-34
   PubMed Web of Science ®Google Scholar
• Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157-69
   PubMed Web of Science ®Google Scholar
• Dhillon S, Weber J. Saxagliptin. Drugs 2009;69:2103-14
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 Diabetes with metformin alone. Diabetes Care 2009;32:1649-55
   PubMed Web of Science ®Google Scholar
• Kulasa K, Edelman S. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid 2010;5:23-37
   PubMedGoogle Scholar
• Goke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-31
   PubMed Web of Science ®Google Scholar
• Zhu F, Song XY. Therapeutic effects of dipeptidyl peptidase-4 inhibitor saxagliptin on patients with type 2 diabetes and its influences on β-cell function. Chinese J Diabetes 2014;22:494-6
   Google Scholar
• Xu Z, Lu M, Zhou Y, et al. Analysis of the use of oral antidiabetic drugs in our hospital from 2009 to 2012. Drug Eval 2013;10:14-18, 44
   Google Scholar
• Freeman JS. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. J Am Osteopath Assoc 2010;110:528-37
   PubMedGoogle Scholar
• Granstrom O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden. Prim Care Diabetes 2012;6:127-36
   PubMed Web of Science ®Google Scholar
• Erhardt W, Bergenheim K, Duprat-Lomon I, et al. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig 2012;32:189-202
   PubMed Web of Science ®Google Scholar
• Elgart JF, Caporale JE, Gonzalez L, et al. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Econ Rev 2013;3:11-19
   PubMedGoogle Scholar
• McEwan P, Peters JR, Bergenheim K, et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006;22:121-9
   PubMed Web of Science ®Google Scholar
• McEwan P, Bergenheim K, Yuan Y, et al. Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. Pharmacoeconomics 2010;28:665-74
   PubMed Web of Science ®Google Scholar
• McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab 2010;12:623-30
   PubMed Web of Science ®Google Scholar
• McEwan P, Evans M, Kan H, et al. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab 2010;2:431-6
   Google Scholar
• Mount Hood Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56:1925-33
   PubMed Web of Science ®Google Scholar
• Sabale U, Ekman M, Granstrom O, et al. Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes 2015;9:39-47
   PubMed Web of Science ®Google Scholar
• National Health and Family Planning Commission of the People's Republic of China. China health statistics yearbook 2013. Beijing, China. 2013. http://www.nhfpc.gov.cn/htmlfiles/zwgkzt/ptjnj/year2013/index2013.html. Accessed 20 April 2015
   Google Scholar
• World Health Organization. The world health report 2002- Chapter 5 (Some strategies to reduce risk– Technical considerations for cost-effectiveness analysis). Geneva, Switzerland. 2002. http://www.who.int/whr/2002/en/Chapter5.pdf?ua=1. Accessed 9 April 2015
   Google Scholar
• Marrett E, Radican L, Davies MJ, et al. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes 2011;4:251
   PubMedGoogle Scholar
• Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabetic Med 2008;25:245-54
   PubMed Web of Science ®Google Scholar
• Zheng YM, Wu J, Xie K. Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus (T2DM). Chinese Rural Health Service Admin 2012;32:1195-8
   Google Scholar
• Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202
   PubMedGoogle Scholar
• Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health 2008;11:478-86
   PubMed Web of Science ®Google Scholar
• Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014;30:1267-73
   PubMed Web of Science ®Google Scholar
• General Administration of Sport of China. National Physique Monitoring Bulletin (2010). Beijing, China. 2011. http://www.sport.gov.cn/n16/n1077/n297454/2052709.html. Accessed 29 December 2014
   Google Scholar
• Ji LN, Hu DY, Pan CY, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 Diabetes patients. Am J Med 2013;126:911-25
   Web of Science ®Google Scholar
• UK PDSG. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (N Am Ed) 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics of the People's Republic of China. Consumer Price Index of Residents. Beijing, China. 2014. http://data.stats.gov.cn/workspace/index?m=hgnd. Accessed 28 November 2014
   Google Scholar
• The Organisation for Economic Co-operation and Development OECD. Conversion rates- Exchange rates. Paris, France. 2014. https://data.oecd.org/conversion/exchange-rates.htm. Accessed 10 April 2015
   Google Scholar
• Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care 2012;28:436-44
   PubMed Web of Science ®Google Scholar
• Li HC, Xu F, Wang F. Cost-effectiveness of biphasic insulin aspart 30 combined with metformin in patients with type 2 diabetes mellitus. Chinese J New Drugs 2011;20:2163-70
   Google Scholar
• Palmer JL, Gibbs M, Scheijbeler H, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther 2008;25:752-74
   PubMed Web of Science ®Google Scholar
• Price Bureau. Official drug price list for saxagliptin. Zhejiang, China. 2014. http://www.zjpi.gov.cn/main/html/2014/CT10046/eec3f13a8b2d46258a93966273078df7.html. Accessed 27 December 2014
   Google Scholar
• Price Bureau. Official drug price list for glimepiride. Zhejiang, China. 2014. http://www.zjpi.gov.cn/main/html/2014/CT10046/dd72e4240a7e4c1da820a849642f7b37.html. Accessed 27 December 2014
   Google Scholar
• Hou XY, Zen Z, Tao X, et al. Cost-effectiveness analysis of 2 dosage forms of metformin hydrochloride in the treatment of type 2 Diabetes. China Pharmacy 2014;25:1844-7
   Google Scholar
• Guo H, Li J, Jiang ZL. Follow-up effects of the increased physical activity on the glucolipid metabolic factors and medical costs in type 2 diabetic patients. Chinese J Rehab Med 2007;22:395-8
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581-90
   PubMed Web of Science ®Google Scholar
• Caro JJ, Stillman IO, Danel A, et al. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ 2007;10:239-54
   Google Scholar
• National Bureau of Statistics of China. Gross Domestic Product (GDP) per capita. Beijing, China. 2013. http://data.stats.gov.cn/search/keywordlist2;jsessionid=387F523D9AF3519917849B593F8A3093?keyword=gdp. Accessed 20 April 2015
   Google Scholar
• Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193-8
   PubMed Web of Science ®Google Scholar
• Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008;10(1 Suppl):43-55
   PubMed Web of Science ®Google Scholar